Medicare Part D coverage · betaxolol · RxCUI 213729
betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S]
Per the CMS 2026 Part D formulary file, betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] is covered by 409 Medicare Part D plans (8.1% of enrollable products), averaging Tier 3.2, with prior authorization required on 2.8% of covering formularies.
- 8.1%
- Plan coverage
- 409
- Plans covering
- T3.2
- Avg tier
- 2.8%
- Prior auth required
What the CMS Formulary Data Shows for betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S]
Per the CMS 2026 Part D formulary file, betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] (RxNorm concept RXCUI 213729, generic name betaxolol) appears on 36 distinct formulary files spanning 409 Medicare Part D plan offerings - 8.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.2.
Real-world access to betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] depends on utilization management as much as tier placement: 2.8% of covering formularies require prior authorization. 2.8% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 7,458 Part D beneficiaries filled betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] in 2023, with total plan-and-beneficiary spending of $2,066,789 and an average per-beneficiary annual cost of $277.12. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] today.
Coverage Details
- Formularies covering
- 36
- Plans covering
- 409
- Coverage rate
- 8.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 2.8% of formularies
- Step therapy required
- 2.8% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 7,458
- Total spending
- $2,066,789
- Avg per beneficiary
- $277.12
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] covered by Medicare Part D?
Yes, betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] is covered by 409 Medicare Part D plans (8.1% of all Part D formularies).
What tier is betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] on Medicare Part D plans?
betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] averages Tier 3.2 across Part D plans, ranging from Tier 1 to Tier 4.
Does betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] require prior authorization?
2.8% of Part D formularies require prior authorization for betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S]. Step therapy: 2.8%. Quantity limits: 0%.
How much does Medicare spend on betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S]?
In 2023, total Medicare Part D spending on betaxolol 2.5 MG/ML Ophthalmic Suspension [Betoptic S] was $2,066,789, covering 7,458 beneficiaries. The average spend per beneficiary was $277.12.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 72 HR fentanyl 0.0625 MG/HR Transdermal System T3.2
- 24 HR lacosamide 200 MG Extended Release Oral Capsule [Motpoly] T3.2
- 0.25 ML paliperidone palmitate 156 MG/ML Prefilled Syringe [Invega] T3.2
- collagenase 0.25 UNT/MG Topical Ointment [Santyl] T3.2
- caspofungin acetate 70 MG Injection T3.2
- 2 ML penicillin G benzathine 450000 UNT/ML / penicillin G procaine 150000 UNT/ML Prefilled Syringe [Bicillin] T3.2
Similar prior-authorization rate
- hydroxyurea 200 MG Oral Capsule [Droxia] 2.8% PA
- ceftaroline fosamil 400 MG Injection 2.7% PA
- ceftaroline fosamil 600 MG Injection 2.7% PA
- entecavir 0.05 MG/ML Oral Solution [Baraclude] 2.7% PA
- pentosan polysulfate 100 MG Oral Capsule [Elmiron] 2.7% PA
- 24 HR methylphenidate hydrochloride 18 MG Extended Release Oral Tablet 2.9% PA